MedTrace Logo

Cardio-Oncology Rehabilitation Care Process

NCT06302634 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2024-03-15

No results posted yet for this study

Summary

The objective of this observational study is to assess the outcomes of a hospital-based Cardio-Oncology Rehabilitation (CORe) program focused on exercise in cancer patients undergoing cardiotoxic treatment. This evaluation will be conducted by analyzing disease-related health indicators, functional capacity, and quality of life. Patients at risk of cardiotoxicity attending the Cardio-Onco-Hematology Unit will be offered the exercise program, which includes two modalities: in-person (center-based) and remote (home-based) options. The assignment to either modality is non randomized, based on the functional assessment conducted in the Rehabilitation Unit and the agreement between healthcare professional and patient. All participants will perform a 3-month supervised exercise intervention. There are 3 time points for assessment: at baseline (T0), 3-month after the exercise program (T1) and follow-up at 9 months from baseline (T2).

Conditions

Interventions

OTHER

Exercise-based cardio-oncology rehabilitation

Within the multidisciplinary approach of cardio-oncology rehabilitation, the exercise program will include recommendation and supervision of strength, aerobic and mobility exercises.

Sponsors & Collaborators

  • Hospital Clinico Universitario de Santiago

    lead OTHER

Principal Investigators

  • Carlos Peña-Gil, MD, PhD · Hospital Clinico Universitario de Santiago

  • Violeta González-Salvado, MD, PhD · Hospital Clinico Universitario de Santiago

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-22
Primary Completion
2027-06-22
Completion
2027-06-22

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06302634 on ClinicalTrials.gov